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Abstract  5 
Antigen presenting cells are critical for regulating immune responses. We 6 
tested mannan-peptide conjugates for targeting myelin peptides to APC to induce T 7 
cell tolerance and resistance to experimental autoimmune encephalomyelitis (EAE). 8 
Myelin peptides conjugated to mannan in oxidized (OM) or reduced (RM) forms 9 
protected mice against EAE in prophylactic and therapeutic protocols, with OM-10 
conjugated peptides giving best results. Protection was peptide-specific and 11 
associated with reduced antigen-specific T cell proliferation, but not alterations in 12 
Th1, Th17 or Treg cell differentiation or T cell apoptosis compared to EAE controls. 13 
OM-MOG-loaded bone marrow-derived DC showed up-regulated expression of co-14 
stimulatory molecules, reduced PD-L1 expression and enhanced CD40-inducible IL-12 15 
and IL-23 production, features consistent with immunogenic DC. OM-MOG induced 16 
active T cell tolerance because i.d. administration or passive transfer of OM-MOG-17 
loaded DC suppressed ongoing EAE, while OM-MOG-vaccinated mice did not reduce 18 
the proliferation of transferred MOG-specific T cells. As in vivo, MOG-specific T cells 19 
cultured with OM-MOG-loaded DC showed reduced proliferation and equal Th1 and 20 
Th17 cell differentiation as those with MOG-loaded DC, but surprisingly cytokine 21 
production was unresponsive to CD40 engagement. Impaired effector T cell function 22 
was further evidenced in spinal cord sections from OM-MOG-vaccinated EAE mice, 23 
where markedly reduced numbers of CD3+ T cells were present, restricted to 24 
leptomeninges and exceptional parenchymal lesions. Our results show that mannan-25 
conjugated myelin peptides protect mice against EAE through the expansion of 26 
antigen-specific Th1 and Th17 cells with impaired proliferation responses and APC-27 
induced co-stimulatory signals that are required for licensing them to become fully 28 
pathogenic T cells.  29 
30 
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 31 
Introduction 32 
 Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS that 33 
shows autoimmune features and causes demyelination, early axonal injury and 34 
progressive neurological impairment. Current treatments induce non-specific immune 35 
or T cell suppression but are only partially effective and are often associated with 36 
adverse effects. Selective treatments that target the immune cells involved in the 37 
pathological processes are needed. One approach is to identify disease-associated 38 
auto-antigens and to induce antigen-specific T cell tolerance. Several experimental 39 
strategies are effective in switching antigen-specific pro-inflammatory IFN-γ-40 
producing Th1 cell responses to IL-4-producing Th2 cell responses or inducing 41 
regulatory T cells or anergy, including oral (Chen, Kuchroo, Inobe, Hafler, and Weiner, 42 
1994) and inhalation (Burkhart, Liu, Anderton, Metzler, and Wraith, 1999) tolerance 43 
or altered peptide ligands (APL) which compete for Ag-specific T cell receptors and 44 
induce differential signaling through the T cell receptor (TCR) resulting in tolerance 45 
(Vergelli, Hemmer, Utz, Vogt, Kalbus, Tranquill, Conlon, Ling, Steinman, McFarland, 46 
and Martin, 1996), (Evavold and Allen, 1991). However, these approaches have not 47 
translated well into the clinic due to lack of efficacy or severe adverse effects such as 48 
hypersensitivity responses (Hafler, Kent, Pietrusewicz, Khoury, Weiner, and Fukaura, 49 
1997), (Bielekova, Goodwin, Richert, Cortese, Kondo, Afshar, Gran, Eaton, Antel, 50 
Frank, McFarland, and Martin, 2000), (Kappos, Comi, Panitch, Oger, Antel, Conlon, 51 
and Steinman, 2000). Another approach is to harness the immune regulatory 52 
properties of professional antigen-presenting cells (APC), particularly dendritic cells 53 
(DC), which are critical not only for the induction of adaptive immune responses to 54 
foreign antigens but also for the maintenance of immune tolerance to self (Steinman, 55 
2008).  56 
 C-type lectin receptors such as DEC205 and the mannose receptor (MR, 57 
CD206) recognize glycosylated self and nonself-antigens, are highly expressed on APC 58 
and have been used successfully for targeting peptide antigens to APC for 59 
presentation to T cells and modulating immune responses (McGreal, Miller, and 60 
Gordon, 2005). In one approach, in vivo targeting of antigens selectively to steady 61 
state (immature) DC by fusing them to an antibody against the DEC205 endocytosis 62 
receptor (Mahnke, Guo, Lee, Sepulveda, Swain, Nussenzweig, and Steinman, 2000) 63 
induced peripheral T cell tolerance in mice (Hawiger, Inaba, Dorsett, Guo, Mahnke, 64 
Rivera, Ravetch, Steinman, and Nussenzweig, 2001). The observation that 65 
simultaneous activation of CD40 with FGK 45 agonistic CD40 antibody changed the 66 
outcome from tolerance to prolonged T cell activation and immunity supported the 67 
concept of immature DC being involved in the induction of tolerance (Hawiger et al., 68 
2001). Mice treated with anti-DEC-205 antibody fused to myelin self-antigens myelin 69 
oligodendrocyte glycoprotein (MOG) (Hawiger, Masilamani, Bettelli, Kuchroo, and 70 
Nussenzweig, 2004) or proteolipid protein (PLP) (Stern, Keskin, Kato, Waldner, 71 
Schallenberg, Anderson, von, Kretschmer, and Strominger, 2010) peptides developed 72 
impaired T cell responses to antigen and showed resistance to EAE induction. In other 73 
approaches, peptide antigens were targeted to the MR which is expressed at high 74 
levels on APC and captures and presents soluble ligands with selectivity for heavily 75 
glycosylated proteins on the surface of yeasts, bacteria and parasites (Sallusto, Cella, 76 
Danieli, and Lanzavecchia, 1995). Peptides that are mannosylated with added sugar 77 
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units (Engering, Cella, Fluitsma, Brockhaus, Hoefsmit, Lanzavecchia, and Pieters, 78 
1997), (Tan, Mommaas, Drijfhout, Jordens, Onderwater, Verwoerd, Mulder, van der 79 
Heiden, Scheidegger, Oomen, Ottenhoff, Tulp, Neefjes, and Koning, 1997) or 80 
chemically conjugated to the mannan polysaccharide (Apostolopoulos, Pietersz, 81 
Gordon, Martinez-Pomares, and McKenzie, 2000) show greatly enhanced 82 
presentation by major histocompatibility complex (MHC) class II and I to T cells. 83 
However, mannosylated peptides did not promote immune responses in vivo. 84 
Instead, immunization of mice with a mannosylated myelin autoantigen, PLP139-151 in 85 
the presence of complete adjuvant containing Mycobacterium tuberculosis, showed 86 
reduced T cell proliferation responses, impaired delayed-type hypersensitivity (DTH) 87 
responses and protected mice against the induction of EAE following immunization 88 
with PLP139-151 (Luca, Kel, van, Wouter, Koning, and Nagelkerken, 2005), (Kel, 89 
Oldenampsen, Luca, Drijfhout, Koning, and Nagelkerken, 2007), (Kel, Slutter, 90 
Drijfhout, Koning, and Nagelkerken, 2008). These findings again support the 91 
participation of APC in mediating tolerance to mannosylated self-antigens and 92 
indicate that targeting antigens to MR may be a powerful strategy to suppress 93 
autoimmune responses.   94 
 Mannan is a yeast polysaccharide that acts as a pathogen-associated 95 
molecular pattern (PAMP) and at high concentrations stimulates the activation of 96 
macrophages (Tada, Nemoto, Shimauchi, Watanabe, Mikami, Matsumoto, Ohno, 97 
Tamura, Shibata, Akashi, Miyake, Sugawara, and Takada, 2002), induces the 98 
phenotypic maturation of DC in a Toll-like receptor 4-dependent manner (Sheng, 99 
Pouniotis, Wright, Tang, Lazoura, Pietersz, and Apostolopoulos, 2006) and enhances 100 
antigen presentation and immune responses (Apostolopoulos et al., 2000). Our 101 
studies have shown that conjugation of the human tumour antigen mucin 1 (MUC1) 102 
to mannan in its oxidized (OM) or reduced (RM) forms leads to its efficient 103 
presentation by MHC class I or MHC class II and the induction of T1 or T2 immune 104 
responses respectively, with OM-MUC1 giving the best IFN-γ-producing cytotoxic T 105 
cell responses and protection against tumour formation (Apostolopoulos et al., 2000), 106 
(Apostolopoulos, Pietersz, Loveland, Sandrin, and McKenzie, 1995). In view of these 107 
results, in this study we investigated the potential of conjugating mannan to self-108 
antigens as a possible strategy for diverting myelin-specific T cell responses towards 109 
an immunomodulatory profile and reducing the susceptibility of mice to EAE. We 110 
show that mannan-conjugated myelin antigens induced peptide-specific T cell 111 
tolerance and strongly ameliorated the clinical signs of EAE when administered to 112 
mice in prophylactic (vaccination) and therapeutic protocols. Surprisingly, however, 113 
tolerance was not associated with immune deviation of the effector T cell response or 114 
the induction of regulatory T cells but with the efficient induction of antigen-specific 115 
Th1 and Th17 cells that were anergic to re-stimulation with cognate antigen and 116 
showed marked reduction of encephalitogenic potential.  117 
 118 
Materials and Methods 119 
Mice 120 
C57BL/6 (CD45.2), SJL/J and C57BL/6-Tg(Tcra2D2, Tcrb2D2)1Kuch/J) (2D2) 121 
mice were purchased from the Jackson Laboratory. C57BL/6 expressing EGFP under 122 
the actin promoter, TgN(act-EGFP)OsbC14-Y01-FM131, (TgEGFP) were kindly 123 
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provided by Masaru Okabe (Osaka University). CD45.1 congenic 2D2 C57BL/6 mice 124 
were kindly provided by Burkhard Becher and Melanie Greter (University of Zurich). 125 
Mice were kept under specific pathogen-free conditions in the experimental animal 126 
unit of the Hellenic Pasteur Institute. All animal procedures were performed to 127 
minimize suffering and conformed to the principles of the three Rs (replacement, 128 
refinement and reduction) following the guidelines of the EU directive for animal 129 
research 2010/63/EU. Experimentation licences were provided by the General 130 
Secretariat of Agricultural Economy and Veterinary Medicine of the Greek State 131 
according to the presidential directive 160/91. The reporting of the animal 132 
experiments in this study follows the ARRIVE guidelines.  133 
 134 
Synthesis of myelin peptides 135 
Peptides (murine MOG35-55, PLP139-151, PLP178-191, myelin basic protein (MBP) 136 
83-99) were synthesized by Fmoc/tBu methodology using the acid sensitive 2-137 
chlorotrityl chloride (CLTR-Cl) resin (0.6-1.0 mmolCl-/g) and Na-Fmoc (9-138 
fluorenylmethyloxycarboxyl)-protected amino acids (Tselios, Probert, Daliani, 139 
Matsoukas, Troganis, Gerothanassis, Mavromoustakos, Moore, and Matsoukas, 140 
1999). The final products were further purified using semi-preparative reverse 141 
phase-high performance liquid chromatography (RP-HPLC). The purity of peptides 142 
was >95% as determined by analytical RP-HPLC and electron spray ionization-mass 143 
spectrometry. All peptides for conjugation with mannan were synthesized using (Lys-144 
Gly)5 at the N-terminus which acts as a linker between the peptide and mannan. The 145 
synthesis of the polypeptide [(Lys-Gly)5]-(Glu, Ala, Tyr, Lys) (POL) was based on the 146 
synthesis of GA (Sela and Mozes, 2004) and involved the polymerization of five 147 
benzotriazolyl esters derived from alanine, γ-tert-butyl-glutamate, Nε-148 
butyloxycarbonyl-lysine, O-tert-butyl-tyrosine and Nα-butyloxycarbonyl-[(Nε-149 
butyloxycarbonyl-lysine)-glycine]5. The side chain-protected units were combined in 150 
an average molar fraction 1 for [(Lys-Gly)5], 1.51 for (Glu), 4.95 for (Ala), 1 for (Tyr), 151 
3.54 for (Lys) in a ratio of 4.95. The 1-hydroxybenzotriazole (5.85 mmol) and N,N’-152 
diisopropylcarbodiimide (4.29 mmol) were added as coupling reagents in 153 
dimethylformamide solvent. The mixture was left to react for 72 h at room 154 
temperature, the solvent was removed on a rotary evaporator and the obtained oily 155 
product was precipitated from water as an amorphous pale yellow solid. The linear 156 
protected polypeptide was treated with 90% trifluoroacetic acid (TFA) in 157 
dichloromethane in the presence of 0.3% triethylsilane, anisole and H2O as 158 
scavengers for 5 hours at room temperature. The solvents were removed on a rotary 159 
evaporator and the obtained oily product was precipitated from cold dry diethyl 160 
ether as amorphous light yellow solid. The crude peptide product was further 161 
purified by semi-preparative RP-HPLC: (column: Nucleosil C18, 5 μm, 4.6x250 mm), 162 
eluents: A, 0.08% TFA/H2O, B, 0.08% TFA/acetonitrile, gradual gradient: from 10% to 163 
60% B in 45 min, flow rate: 3 ml/min, detection 230 nm, 254 nm, 277 nm. All the 164 
fractions between 13-15 min were collected, lyophilized and passed through a pre-165 
packed column Sephadex G-25 Medium to remove the low molecular weight 166 
contaminants (Mr < 1000). 167 
 168 
Conjugation of peptides to mannan 169 
Peptide-mannan conjugation was achieved as previously described 170 
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(Apostolopoulos, Pietersz, and McKenzie, 1996). Briefly, mannan (poly-mannose 171 
from Saccharomyces cerevisiae; Sigma-Aldrich Ltd) in phosphate buffer (pH 6.0) was 172 
oxidized to polyaldehydes by treating with sodium periodate. The conjugation of 173 
peptides to oxidized mannan (OM) was achieved via Schiff base formation between 174 
the free amino groups of Lys and the aldehydes of OM in bicarbonate buffer (pH 175 
9.0). Reduction of the free aldehydes and Schiff base to alcohols and amines 176 
respectively, to form reduced mannan (RM), was achieved by treating the OM-177 
peptide complex with sodium borohydride. Conjugates were analysed for 178 
conjugation efficiency by capillary electrophoresis as previously reported (Tselios, 179 
Lamari, Karathanasopoulou, Katsara, Apostolopoulos, Pietersz, Matsoukas, and 180 
Karamanos, 2005).   181 
 182 
Administration of mannan-peptide conjugates to mice 183 
In a prophylactic vaccination protocol, groups of female C57BL/6 or SJL/J 184 
mice (6-8 weeks old) were injected intradermally (i.d.) on the flanks with 100 μl PBS 185 
containing OM-MOG35-55 (OM-MOG), RM-MOG35-55 (RM-MOG), OM-PLP178-191, OM-186 
POL, RM-POL or an unconjugated mixture of OM and MOG35-55 (MOG) (in the 187 
C57BL/6 strain), and OM-PLP139-151 or OM-MBP83-99 (in the SJL/J strain) (all 30 μg 188 
peptide equivalent/injection and 700 μg mannan equivalent/injection). As controls, 189 
age-matched groups of mice were vaccinated with OM or RM (700 μg), 190 
unconjugated peptide (30 μg) or PBS vehicle. Three consecutive injections were 191 
performed at 15-day intervals. Immunization for the induction of EAE was performed 192 
15 days after the last i.d. injection. In therapeutic administration protocols, groups of 193 
female C57BL/6 mice (6-10 weeks old) were injected i.d. with 100 μl PBS containing 194 
peptide conjugates or controls, as above, at the time of immunization (day 0) and 7 195 
later, or after the onset of clinical signs, as indicated.   196 
 197 
EAE induction 198 
MOG-EAE was induced in 6-8 week-old female C57BL/6 mice (17-18 week-old 199 
bone marrow chimeric mice) by subcutaneous (s.c.) tail-base injection of 30 μg of 200 
murine MOG35–55 in 100 μl PBS emulsified in an equal volume of complete Freund’s 201 
adjuvant (CFA), 15 days after the third vaccine injection. Mice received 202 
intaperitoneal (i.p.) injections of 200 ng of Bordetella pertussis toxin (PTx) (Sigma-203 
Aldrich) at the time of immunization and 48 h later. In some experiments an 204 
agonistic rat IgG antibody to mouse CD40 (FGK45) (Rolink, Melchers, and Andersson, 205 
1996) kindly provided by Antonius Rolink, University of Basel) was administered i.p. 206 
(90 μg / mouse) from day 2 post-immunization and thereafter twice-weekly for 2 207 
weeks (total of 5 injections). PLP-EAE was induced in female SJL/J mice by s.c. tail-208 
base injection of 150 μg of PLP139-151 emulsified in CFA, 15 days after the third 209 
vaccine injection, without the administration of PTx. CFA used in all experiments was 210 
supplemented with 400 μg/injection of H37Ra Mycobacterium tuberculosis (Difco). 211 
Mice were monitored daily for the clinical signs of EAE according to the following 212 
scores: 0, normal; 1, limp tail; 2, hind limb weakness; 3, hind limb paralysis; 4, 213 
forelimb paralysis; and 5, moribund or dead (0.5 gradations represent intermediate 214 
scores). Moribund animals were euthanized and given a clinical score of 5 for the 215 
remaining days of the experiment. All mice were allowed free access to food and 216 
water throughout the experiments.  217 
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 218 
TgEGFP bone marrow chimeric mice 219 
Bone marrow cells were flushed from tibia and femur bones of naïve female 220 
TgEGFP mice and red blood cells were lysed using ammonium chloride potassium 221 
(ACK) buffer. Washed cells were transplanted i.v. to lethally irradiated female 222 
C57BL/6 recipients (5-6 weeks old) (5x106 / mouse). Efficiency of bone marrow 223 
engraftment was determined after 6 weeks of recovery by FACS analysis for GFP 224 
expression in peripheral blood cells. Mice showing >70% EGFP+ blood cells were used 225 
for vaccination with OM-MOG or PBS control and induction of MOG-EAE and were 226 
sacrificed for immunohistochemical analysis of TgEGFP cell distribution in peripheral 227 
(gut, lung) and CNS tissues, and spinal cord lesion development (see below) in tissues 228 
taken at the peak of clinical disease in the control group.   229 
 230 
Bone marrow-derived DC culture and in vivo transfer 231 
Bone marrow-derived DC were isolated as previously described (Lutz, 232 
Kukutsch, Ogilvie, Rossner, Koch, Romani, and Schuler, 1999). Bone marrow cells 233 
were isolated from naive C57BL/6 mice as described above and cultured at 3 x 106 234 
cells per plate in 10 ml of RPMI 1640 supplemented with 10% heat inactivated FBS 235 
for 9 days. Cells were treated with 20 ng/ml of recombinant GM-CSF (Sigma) on days 236 
0, 3 and 6 to stimulate differentiation. Adherent cells were harvested on day 9 and 237 
loaded in vitro with OM-MOG, MOG, OM or PBS (10 μg/ml peptide equivalent and 238 
233 μg/ml mannan equivalent). After 24 h, the phenotype of the CD11c+ cells was 239 
evaluated by staining with fluorochrome-labeled antibodies for cell surface markers 240 
(MHC class II (anti-I-A/I-E), CD8a, CD80, CD86, CD40) and intracellular staining for 241 
PD-L1 using a FACSCalibur cytometer and CellQuest software (BD). Production of IL-242 
23 and IL-12p70 was measured in DC supernatants by ELISA (see below). As a 243 
positive control for DC maturation, cells were stimulated with LPS (1μg/ml) derived 244 
from E. coli (Sigma). Cells were used in DC-T cell co-culture assays or for adoptive 245 
transfer into mice. For in vivo experiments, peptide-loaded DC (1 x 106 cells/mouse) 246 
were transferred i.v. to C57BL/6 recipient mice on day 8 post-immunization for 247 
MOG-EAE induction, just before the onset of clinical signs, and mice were scored 248 
daily for clinical signs of EAE. 249 
 250 
T cell proliferation and death assays 251 
Splenocytes or draining lymph node (DLN) cells were isolated from 252 
immunized C57BL/6 mice and cultured for 72 h in RPMI 1640 (Invitrogen Life 253 
Technologies) supplemented with 10% heat-inactivated FCS, 50 μM 2-β 254 
mercaptoethanol (Sigma), and increasing concentrations of MOG peptide. Cells were 255 
stimulated in triplicate at 2x106 cells / ml in round-bottom 96-well plates (Costar). 256 
Cells were pulsed with 1 μCi / 5x105 cells [3H]-thymidine (Amersham Radiochemicals) 257 
for the last 16 h of culture. [3H]-Thymidine incorporation was measured by liquid 258 
scintillation counting (Wallac). Results are expressed as the stimulation index (SI) 259 
calculated from the radioactivity counts per minute (cpm) of cells cultured in the 260 
presence of peptide divided by cpm of cells cultured in medium alone.  261 
To measure T cell proliferation in vivo, splenocytes and DLN cells were 262 
isolated from CD45.1 congenic MOG35-55-specific T cell receptor (2D2) transgenic 263 
donor mice (Bettelli, Pagany, Weiner, Linington, Sobel, and Kuchroo, 2003) and 264 
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labeled with 5-(and 6-) carboxyfluorescein diacetate, succinimidyl ester (CFSE) 265 
(CFDA-SE; Molecular Probes). Cells were washed and resuspended at a concentration 266 
of 107/ml in PBS. CFSE was added at a final concentration of 5 μM and incubated for 267 
5 min at RT. The reaction was stopped by washing the cells with RPMI 1640 (Life 268 
Technologies) containing 10% FCS. Cells (10 x 106 cells/mouse) were injected i.v. in 269 
the tail vain of vaccinated, CD45.2 recipient mice on day 2 post-immunization for 270 
MOG-EAE induction. On day 7 of EAE DLN cells were isolated and analyzed by flow 271 
cytometry.  272 
Measurement of CD4+ T cells undergoing apoptotic cell death after prolonged 273 
stimulation with peptide-loaded DC in DC-T cell co-cultures (assayed at days 6, 7, 9, 274 
12 of culture) was made using the FITC Annexin V apoptosis detection kit (BD 275 
Pharmingen).  276 
 277 
Cell phenotyping and cytokine production 278 
For intracellular cytokine staining mononuclear cells stimulated for 3h with 279 
PMA and ionomycin in the presence of Brefeldin A, were fixed in 2% 280 
paraformaldehyde solution in PBS for 10 min at room temperature and 281 
permeabilized with 0.5% wt/vol saponin prior to staining for surface markers and 282 
intracellular cytokines using fluorochrome-labeled antibodies (anti-CD4, clone L3T4; 283 
anti-CD45.1, clone A20; anti-CD11c, clone HL3; anti-CD8a, clone 53-6.7; anti-CD40, 284 
clone 3/23; anti-CD80, clone 16-10A1; anti-CD86, clone GL1; anti-I-A/I-E (MHC class 285 
II), clone 2G9; anti-IL-17, clone TC11-18H10; anti-IFN-γ, clone XMG1.2; anti-FoxP3, 286 
clone; FJK-16s; anti-PD-L1 (CD274), clone MIH5; IgG1 isotype control, clone R3-34; 287 
IgG2a isotype control, clone B39-4 all from BD Biosciences). Data was acquired and 288 
analyzed with a FACSCalibur cytometer and CellQuest software (BD) and with 289 
FlowJo, version 10.0.6 (Tree Star). The production of IL-23 and IL-12p70 by DC was 290 
measured in cell supernatants by mouse ELISA Ready-SET-Go kits (e-Bioscience) 291 
(sensitivity for IL-12p70 at 15 pg/ml and for IL-23 at 8 pg/ml). 292 
 293 
DC-T cell antigen presentation assays 294 
Splenocytes and DLN cells were isolated from 2D2 mice and co-cultured at 2 x 295 
105 cells/well in 96 well plates with peptide-loaded DC at different ratios. All 296 
combinations of responder and stimulator cells were cultured in triplicate for 72 h. 297 
Cell proliferation was measured by [3H]-thymidine incorporation and cytokine 298 
production was measured by intracellular cytokine staining as described above. In 299 
experiments with CD40 costimulation, cells were incubated for 72 h in the absence 300 
or presence of agonistic anti-CD40 antibody FGK45 (10 μg/ml).  301 
For T helper cell polarization experiments, splenocytes and peripheral LN 302 
cells were isolated from 2D2 mice and co-cultured with peptide-loaded, in vitro 303 
matured, bone marrow-derived DC. The polarization conditions were: Th1 culture; 304 
IL-12 (10 ng/ml, Peprotech), anti-IL4 (10 μg/ml, R&D systems): Th17 culture; IL-6 (50 305 
ng/ml, Peprotech), IL-23 (10 ng/ml, eBioscience), TGF-β (5 ng/ml, Peprotech), anti-306 
IFN-γ (10 μg/ml, R&D systems): Treg culture; TGF-β (10 ng/ml, Peprotech), anti-IFN-γ 307 
(10 μg/ml, R&D systems), anti-IL-4 (10 μg/ml, R&D systems). On day 3 of culture, Th1 308 
and Treg polarizing cultures were supplemented with IL-2 (10 ng/ml, Peprotech) and 309 
Th17 polarizing cultures were supplemented with IL-23 (10 ng/ml). Cells were 310 
harvested on day 5 for FACS analysis of lineage markers.   311 
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 312 
 313 
Histopathological analysis 314 
Mice were transcardially perfused with ice-cold 4% paraformaldehyde in PBS 315 
under deep anaesthesia. CNS tissues were post-fixed in the same fixative for 3 h at 316 
4°C and processed for standard histopathological analysis. Inflammation was 317 
visualized by staining with H&E and demyelination was demonstrated by Luxol Fast 318 
Blue/periodic acid-Schiff staining. Quantification of inflammation and demyelination 319 
was done in a blinded manner. Inflammation in the spinal cord was determined by 320 
absolute true quantification; the numbers representing inflammatory 321 
infiltrates/mm2 of tissue. In the brain a semi-quantitative scoring of inflammation 322 
was used in which, 0.5 means single perivascular infiltrates and 1 means multiple 323 
inflammatory infiltrates. Demyelination was also evaluated by semi-quantitative 324 
scoring as follows: 0.5: single perivascular sleeves of demyelination, 1: ubiquitous 325 
perivascular or subpial demyelination, 2: confluent demyelinated plaques, 3: 326 
profound focal demyelination, involving about 1/2 of the spinal cord white matter at 327 
least in one spinal cord segment, 4: extensive demyelination, for instance complete 328 
demyelination of spinal cord white matter at least in one segment of the spinal cord. 329 
 330 
Immunohistochemistry 331 
Immunohistochemistry was performed on paraffin sections (4 μm) to evaluate tissue 332 
distribution of TgEGFP bone marrow-derived immune cells, CD3+ T cells as well as 333 
production of the p22phox subunit of NADPH oxidase and iNOS by inflammatory 334 
macrophages. Antigen retrieval in paraffin sections was performed in a food steamer 335 
in citrate buffer (pH 6) for 40 min. The primary Abs used were polyclonal rabbit anti-336 
GFP IgG (1/200; Molecular Probes; A11122), monoclonal rabbit anti-CD3 (1/2000; 337 
Neomarkers; RM-9107), polyclonal rabbit anti-p22phox (1/100; Santa Cruz Biotech; 338 
sc-20781) and polyclonal rabbit anti-rat iNOS (1/375; Chemicon; AB1631) followed 339 
by biotinylated secondary anti-IgG Ab (1/500; Vector laboratories). An avidin-biotin 340 
complex was used for detection of the biotinylated Abs and immune complexes 341 
were visualized by incubation with 3,3’-diaminobenzidine tetrachloride (DAB) (both 342 
from Vector laboratories). 343 
 344 
Statistical analysis 345 
All statistical analyses were performed with Sigma Stat 3.5, Sigma Plot 11 and 346 
Microsoft Excel. All data are given as mean ± standard error of the mean (SEM). 347 
Student’s t test and Kruskal-Wallis test were used. Results were considered 348 
statistically significant when p<0.05.  349 
 350 
 351 
 352 
Results 353 
Administration of OM- or RM-MOG prophylactically or therapeutically protects mice 354 
against MOG-EAE 355 
 To examine the effect of the H-2b binding MOG35-55 peptide (MOG) conjugated 356 
to oxidized mannan (OM-MOG) or reduced mannan (RM-MOG) upon the 357 
development of MOG-EAE, we delivered peptide conjugates to C57BL/6 (H-2b) mice in 358 
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a prophylactic vaccine protocol prior to the induction of EAE by immunization with 359 
MOG emulsified in CFA and administration of Bordetella pertussis toxin 360 
(MOG/CFA/PTx). Three intradermal (i.d.) injections of OM- or RM-MOG, but not 361 
unconjugated OM, RM, MOG or a mixture of unconjugated OM and MOG (OM/MOG) 362 
in dilute soluble form and spaced at 15 day intervals prior to immunization with 363 
MOG/CFA/PTx, protected mice from the subsequent development of EAE compared 364 
to PBS (Fig. 1a, Supplementary Fig. 1a), with OM-MOG giving increased protection 365 
when compared to RM-MOG (Fig. 1a).  366 
We next tested the effects of mannan-conjugated peptides when 367 
administered in therapeutic protocols in the presence of adjuvants and PTx. In one 368 
approach peptide conjugates were injected i.d. on the day of EAE induction with 369 
MOG/CFA/PTx and again seven days later. OM-MOG and RM-MOG, but not 370 
unconjugated OM, RM, or MOG, showed protective effects compared to PBS. With 371 
this protocol protection by OM-MOG and RM-MOG showed statistically similar levels 372 
of protection up to the last time point tested (Fig. 1b). In a second approach we 373 
injected OM-MOG after the onset of MOG-EAE, when mice have reached at least 374 
clinical score 2 and found that OM-MOG rapidly reduced the severity of ongoing 375 
disease, with the clinical condition of the experimental animals progressively 376 
improving upon each injection (Fig. 1c).  377 
In conclusion, i.d. administration of OM-MOG strongly protected mice against 378 
clinical MOG-EAE in all prophylactic and therapeutic treatment protocols tested, 379 
even in the presence of PTx and activated encephalitogenic T cells, and OM-380 
conjugated peptides were chosen for subsequent experiments investigating the 381 
mechanism of tolerance induced by mannan-conjugated self-antigens.  382 
 383 
Vaccination with OM-MOG and RM-MOG protects mice against EAE neuropathology  384 
To determine whether amelioration of the clinical signs of MOG-EAE by OM- 385 
and RM-MOG was associated by less severe neuropathology, vaccinated mice were 386 
sacrificed 24 days after EAE induction for neuropathological analysis of spinal cord 387 
and brain tissues (Fig. 1d and e). PBS-treated mice showed substantial mononuclear 388 
cell infiltration and extensive demyelination in the spinal cord. In contrast, mice 389 
vaccinated with OM-MOG showed reduced inflammatory cell infiltration and little or 390 
no demyelination in the spinal cord. RM-MOG-vaccinated mice showed reduced 391 
neuropathology compared to PBS-treated mice. Mice vaccinated with unconjugated 392 
MOG, OM or RM showed equivalent spinal cord pathology to PBS-treated animals 393 
(Fig. 1d). A quantitative assessment of demyelination and inflammation in each 394 
individual mouse confirmed that CNS pathology in OM-MOG-vaccinated mice was 395 
significantly reduced compared to PBS-treated mice (Fig. 1e).  396 
We conclude that the administration OM-MOG as a prophylactic vaccine in 397 
mice inhibits the accumulation and infiltration of immune cells into the CNS 398 
parenchyma during EAE and the development of inflammatory and demyelinating 399 
lesions. 400 
Protection from EAE by mannan-conjugated peptides is peptide-specific 401 
To determine whether protection by mannan-peptide conjugates can apply 402 
to other CNS antigens and also whether it depends on peptide specificity, we next 403 
performed peptide criss cross experiments where we complemented the MOG-EAE 404 
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model with another EAE model in SJL/J mice (H-2s) in which disease is induced by 405 
immunization with the H-2s binding peptide, proteolipid protein 139-151 (PLP) 406 
(McRae, Kennedy, Tan, Dal Canto, Picha, and Miller, 1992). OM was conjugated to 407 
PLP (OM-PLP) or another H-2S binding peptide, myelin basic protein 83-99, which 408 
itself is capable of inducing EAE when used to immunize SJL/J mice (Miller, Karpus, 409 
and Davidson, 2010), as peptide control. Groups of SJL/J mice were vaccinated, as 410 
above, with OM-PLP139-151, OM-MBP83-99 or PBS. Fifteen days after the last injection, 411 
EAE was induced by immunization with PLP139-151 in CFA (PLP/CFA). Control mice 412 
vaccinated with PBS developed acute severe clinical signs typical of PLP-EAE (Fig. 2a). 413 
As in the MOG-EAE model, mice vaccinated with mannan-conjugated to cognate 414 
peptide, OM-PLP139-151, but not irrelevant peptide OM-MBP83-99, were strongly 415 
protected against PLP-EAE (Fig. 2a). In the crossover experiment using the MOG-EAE 416 
model, OM was conjugated to another H-2b-binding peptide, PLP 178-191 which 417 
itself is capable of inducing EAE in C57BL/6 mice (Tompkins, Padilla, Dal Canto, Ting, 418 
Van, and Miller, 2002), as peptide control. Groups of C57BL/6 mice were vaccinated 419 
with OM-MOG35-55, OM-PLP178-191 or PBS and fifteen days after the last injection EAE 420 
was induced by immunization with MOG/CFA/PTx. As predicted, mice vaccinated 421 
with OM-MOG35-55, but not OM-PLP178-191, were strongly protected against MOG-EAE 422 
(Fig. 2b). 423 
In a second approach we used the MOG-EAE model to test the prophylactic 424 
efficacy of OM and RM conjugated to a polypeptide mixture of synthesized randomly 425 
from four amino acids (L-Glutamic acid, L-Lysine, L-Alanine and L-Tyrosine) based on 426 
GA [30] (Glu, Ala, Tyr, Lys) (POL), which has been shown to induce T cell tolerance in 427 
MOG-EAE and is used in the treatment of MS (Sela et al., 2004). Groups of C57BL/6 428 
mice were vaccinated, as above, with OM- and RM-POL conjugates or unconjugated 429 
OM, RM or POL with or without the [(Lys-Gly)5] linker. Fifteen days after the last 430 
injection, mice were immunized with MOG/CFA/PTx to induce EAE. Under these 431 
conditions all mice, including those injected with POL, developed EAE with 432 
equivalent severity and timing as PBS-injected controls (Supplementary Fig. 1b).  433 
We conclude that the induction of T cell tolerance by mannan-conjugated 434 
peptides applies in different EAE models and is peptide-specific, at least during the 435 
time frame of our experiments, applying only to the peptide used to immunize mice 436 
for the induction of EAE.  437 
 438 
Antigen-specific responses of T cells exposed to OM-MOG show reduced proliferation 439 
but efficient expansion of Th1, Th17 and Treg populations 440 
To determine whether the therapeutic effects of OM-MOG in MOG-EAE were 441 
associated with alteration of antigen-specific immune responses, we compared T cell 442 
responses to MOG immunization in mice that had been previously treated with the 443 
different vaccination components. Mice were immunized with MOG/CFA/PTx 15 444 
days after the last vaccine injection and DLN and/or splenocytes were isolated at 445 
different time points prior to and after the onset of clinical signs in the PBS-treated 446 
group, re-stimulated with MOG peptide in vitro and analyzed for proliferation and 447 
effector T cell cytokine production. Time points analyzed were pre-onset (days 7 & 448 
10 post-immunization), peak of EAE (day 15) and chronic EAE (day 25). Antigen-449 
specific proliferation responses were measured in splenocytes isolated 25 days post-450 
immunization with MOG/CFA/PTx and restimulated with MOG35-55 peptide in vitro. 451 
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Lymphocytes from mice vaccinated with OM-MOG or RM-MOG, but not OM, RM, or 452 
MOG showed reduced antigen-induced proliferation responses compared to PBS 453 
(Fig. 3a, and data not shown). Similar results were obtained using DLN cells isolated 454 
from vaccinated mice 10 days post-immunization with MOG/CFA and restimulated 455 
with MOG35-55 peptide in vitro (data not shown). The percentages of total CD4
+ T cells 456 
isolated from the DLN and spleens of mice from different vaccination groups were 457 
similar following immunization (Supplementary Fig. 2).  458 
We next examined whether T cells isolated from naïve MOG35-55-specific T 459 
cell receptor (2D2) transgenic donor mice (Bettelli et al., 2003), and transferred into 460 
recipient mice that had been previously vaccinated with OM-MOG, would acquire 461 
tolerance at a time when OM-MOG was no longer present in the recipient mouse. 462 
Splenocytes were isolated from 2D2 CD45.1 donor mice, labelled ex vivo with CFSE 463 
and adoptively transferred into vaccinated CD45.2 recipient mice, 17 days after the 464 
last i.d. injection of OM-MOG and 2 days after immunization with MOG/CFA/PTx. 465 
Analysis of fluorescence in the transferred CFSE-labeled 2D2 CD45.1 T cells isolated 466 
from DLN 7 days post-immunization showed that, unlike the endogenous cells, there 467 
were no differences in the proliferation of exogenously administered cells between 468 
mice vaccinated with OM-MOG, OM, MOG or PBS (Fig. 3b). This result indicates that 469 
the presentation of OM-MOG to T cells is required for the induction of long-lasting 470 
reduction in antigen-specific T cell proliferation capacity and that tolerance is not 471 
transferred in the absence of OM-MOG. 472 
Unexpectedly, the expansion of effector T helper cell populations was 473 
unaffected in OM-MOG-vaccinated mice, as Th1 and Th17 populations were equal to 474 
those in control mice. Thus, CD4+IFNγ+ and CD4+IL-17+ DLN (day 7) (Fig. 4c) and 475 
CD4+IL-17+ DLN (Fig. 4d, left panel) and splenocytes (Fig. 4d, right panel) (days 10 and 476 
15) showed no differences from control mice or other vaccination groups as 477 
measured by intracellular cytokine staining. Also, no IL-4 was detectable upon 478 
restimulation of cells from any of the vaccinated groups (data not shown), indicating 479 
that there was no overt emergence of Th2 cells in OM-MOG-vaccinated mice. In one 480 
experiment, in which DLN were isolated on day 13 post-immunization with 481 
MOG/CFA/PTx from mice that were treated with OM-MOG or OM on days 0 and 7 482 
post-immunization (therapeutic protocol), the production of IL-10 in CD4+ T cells 483 
was reduced in OM-MOG-treated mice compared to OM-treated controls (Fig. 3e).  484 
The induction of regulatory T cells is a critical mechanism of tolerance in EAE 485 
where they limit encephalitogenic T cell expansion and function (Kohm, Carpentier, 486 
Anger, and Miller, 2002). We measured the induction of regulatory T cell populations 487 
in mice that were vaccinated with the various peptide conjugates and subsequently 488 
immunized with MOG/CFA. DLN were isolated 7 days post-immunization and CD4+ T 489 
cells were analyzed for Foxp3 expression, the signature transcription factor of 490 
regulatory T cells. The proportions of CD4+ Foxp3+ T cells were not significantly 491 
altered in OM-MOG-vaccinated mice compared to PBS-, OM- and MOG-vaccinated 492 
control groups (Fig. 3f).  493 
In conclusion, OM-MOG exposure of T cells induces lasting peripheral T cell 494 
tolerance that is associated with reduced antigen-specific proliferation responses but 495 
not altered expansion of effector Th1 and Th17 T cells, immune deviation or the 496 
induction of regulatory T cell populations. 497 
 498 
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OM-MOG-loaded DC up-regulate maturation markers, Th1 and Th17 polarising 499 
cytokines,  down-regulate PD-L1 and are sufficient to transfer tolerance into EAE 500 
mice 501 
The MR is expressed by APC, mainly macrophages and DC (Sallusto et al., 502 
1995), (Linehan, Martinez-Pomares, Stahl, and Gordon, 1999) and mediates innate 503 
activation signals from PAMPs such as mannan (Tada et al., 2002). To investigate 504 
whether murine DC can present OM-MOG to T cells and participate in the induction 505 
of tolerance in vaccinated mice we cultured bone marrow-derived DC, loaded them 506 
with the vaccine components ex vivo and used them for antigen presentation assays 507 
in vitro and adoptive transfer experiments in mice. Peptide-loaded DC were first 508 
analysed for the expression of DC maturation markers. CD11c+CD8--gated DC, loaded 509 
with unconjugated OM or OM-MOG (OM-MOG DC), showed increased expression 510 
CD40, CD80 and CD86 compared to those loaded with MOG and PBS, showing levels 511 
of CD40 and CD80 at least as high as in LPS-treated DC (1 μg/ml), while proportions 512 
of MHC class II-expressing cells were equivalent in the peptide-loaded and control 513 
populations (Fig. 4a). These results confirm that OM, in either unconjugated or 514 
peptide-conjugated form, induces phenotypic maturation of in vitro DC. In contrast, 515 
CD11c+CD8--gated DC loaded with MOG (MOG DC) did not show upregulation of 516 
activation markers compared to control PBS DC confirming that unconjugated 517 
peptide does not induce phenotypic maturation of DC (Fig. 4a).  518 
We next compared effector cytokine secretion by OM-MOG and MOG DC in 519 
the absence or presence of CD40 costimulation by FGK 45 agonistic anti-CD40 520 
antibody (Rolink et al., 1996). CD40 is a costimulatory receptor on APC that is 521 
triggered by CD40 ligand produced by strongly activated CD4+ T cells. It boosts 522 
immune responses through the induction of T cell polarizing cytokines and is 523 
essential for licensing DC to induce development of functional effector cells (Albert, 524 
Jegathesan, and Darnell, 2001), (Fujii, Liu, Smith, Bonito, and Steinman, 2004), 525 
(Sporri and Reis e Sousa, 2005), (Iezzi, Sonderegger, Ampenberger, Schmitz, 526 
Marsland, and Kopf, 2009) and for the development of MOG-EAE (Becher, Durell, 527 
Miga, Hickey, and Noelle, 2001), (Iezzi et al., 2009). OM-MOG DC showed increased 528 
production of the Th1 and Th17 polarising cytokines, IL-12 and IL-23 respectively, 529 
compared to MOG DC and production in both cultures was increased by CD40 530 
engagement with FGK 45 (Fig. 4b). We next tested whether OM-MOG-induced 531 
tolerance could be associated with altered production of programmed death ligand-532 
1 (PD-L1), an APC-expressed ligand that negatively regulates TCR signalling via PD-1 533 
on T cells and actively terminates antigen-specific T cell responses including those 534 
that induce EAE (Carter, Leach, Azoitei, Cui, Pelker, Jussif, Benoit, Ireland, Luxenberg, 535 
Askew, Milarski, Groves, Brown, Carito, Percival, Carreno, Collins, and Marusic, 536 
2007). Interestingly, we found production of PD-L1 to be decreased in CD11c+ OM-537 
MOG DC compared to MOG-, OM- and PBS-loaded DC (Fig. 4e). 538 
To directly evaluate whether in vitro grown, OM-MOG-loaded DC showing 539 
expression of maturation markers and up-regulated Th1 and Th17 polarising 540 
cytokines, are sufficient to actively induce tolerance in mice with on-going EAE, we 541 
adoptively transferred MOG-, OM-MOG-, OM- or PBS-loaded DC into non-vaccinated 542 
recipient mice, 8 days after EAE induction by immunization with MOG/CFA/Ptx. 543 
Previous studies have shown that bone marrow-derived DC from Lewis rats with EAE 544 
(Xiao, Huang, Yang, Xu, and Link, 2001) or CD11c+CD11b+ DC isolated from MOG-545 
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tolerized mice (Li, Zhang, Chen, Xu, Fitzgerald, Zhao, and Rostami, 2008) are 546 
sufficient to transfer peptide-specific resistance to EAE in naïve recipients, a property 547 
associated with their immature status. While none of the transferred DC populations 548 
prevented disease onset, both MOG DC and OM-MOG DC, and not OM DC or PBS 549 
DC, reduced the severity of clinical symptoms during the chronic phase of disease 550 
compared to PBS DC (Fig. 4c). Together these results show that immature MOG DC 551 
and phenotypically mature OM-MOG DC are both competent and sufficient to 552 
actively transfer tolerance and reduce clinical symptoms in mice with on-going EAE, 553 
although possibly by different mechanisms.  554 
 555 
OM-MOG DC induce normal maturation of MOG-specific Th1 and Th17 556 
responses but reduced T cell proliferation and CD40 costimulation responses  557 
To further assess the ability of OM-MOG DC to present cognate antigen to T 558 
cells and to investigate the cellular mechanism of OM-MOG-induced tolerance we 559 
performed in vitro antigen presentation assays between peptide-loaded DC and 560 
MOG-specific 2D2 T cells in the absence of presence of FGK 45 , and measured T cell 561 
responses as readout. Bone marrow-derived DC were loaded with peptide 562 
conjugates ex vivo, co-cultured with lymphocytes from 2D2 transgenic mice under 563 
neutral, and in some experiments Th1, Th17 and Treg polarising conditions and T cell 564 
proliferation and cytokine responses to MOG were measured. Both MOG and OM-565 
MOG DC induced robust proliferation responses in 2D2 T cells and these responses 566 
were further enhanced by the presence of FGK 45. However, proliferation induced 567 
by OM-MOG DC was significantly lower than that induced by MOG-loaded DC at two 568 
DC-T cell ratios tested, 1:1 (data not shown) and 1:5 (Fig. 5a). MOG and OM-MOG DC 569 
also efficiently and equally induced the maturation of Th1 and Th17 effector T cell 570 
populations under neutral (Fig. 5b), as well as Th1, Th17 and Treg polarizing 571 
(Supplementary Fig. 3), conditions, an effect in line with the observation of normal 572 
priming of CD4+IL-17+ and CD4+IFNγ+ T cells in response to MOG immunization in 573 
OM-MOG-vaccinated mice (see Fig. 3). Interestingly however, while FGK 45 boosted 574 
cytokine production induced by MOG DC, it had no effect on IFNγ or IL-17 production 575 
induced by OM-MOG DC (Fig. 5b) suggesting that OM-MOG-stimulated T cells, 576 
besides showing reduced antigen-specific proliferation, also show anergy to CD40 577 
co-stimulation of effector cytokine production.  578 
To investigate whether the reduced proliferation of MOG-specific CD4+ T cells 579 
observed in vitro and in vivo was associated with increased T cell death, we assessed 580 
cell surface annexin V staining in the DC-T cell co-cultures after prolonged 581 
stimulation of 2D2 T cells with peptide-loaded DC. The translocation of annexin V to 582 
the cell surface of CD4+ T cells is an early event in apoptotic death occurring after cell 583 
activation. CD4+ T cell surface annexin V staining was not increased in OM-MOG or 584 
MOG DC cultures compared to PBS and OM DC cultures when measured at several 585 
culture time points (representative culture at day 7 postactivation; Fig. 5c). The 586 
finding that OM-MOG DC do not increase apoptosis in MOG-specific T cells indicates 587 
that the reduced proliferation of MOG-specific lymphoblasts seen in OM-MOG-588 
vaccinated mice and OM-MOG DC-T cell co-cultures is not due to increased cell 589 
death.   590 
Since cell types other than DC express MR, including macrophages, some 591 
endothelial cells and perivascular microglia (Linehan et al., 1999), we next 592 
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investigated whether CD40 co-stimulation of APC in vivo could change the outcome 593 
of EAE resistance in OM-MOG-vaccinated mice. We administered FGK45 (90 μg/ 594 
injection) i.p. twice-weekly starting 17 days after the last i.d. injection of OM-MOG 595 
and 2 days after immunization with MOG/CFA/PTx for the induction of EAE. FGK45 596 
administration caused a temporary delay but subsequent enhancement of clinical 597 
signs in control PBS-vaccinated mice compared to non-treated controls (Fig. 5d). In 598 
contrast, FGK45 did not alter the susceptibility of OM-MOG vaccinated mice to 599 
disease. Both FGK45-treated and non-treated OM-MOG-vaccinated mice remained 600 
disease-free up to the last time-point studied (Fig. 5d).  601 
To investigate whether T cells exposed to OM-MOG DC showed anergy we 602 
repeated the proliferation assay in the presence of exogenous IL-2. The proliferation 603 
of 2D2 T cells stimulated with OM-MOG DC was significantly increased by IL-2, up to 604 
the level shown by control cells cultured with MOG DC. The proliferation of 2D2 T 605 
cells stimulated with MOG DC was not further stimulated by IL-2 (Fig. 5e)  606 
We conclude that OM-MOG DC efficiently provide the initial activation signals 607 
for antigen-specific Th1 and Th17 T cell responses but that these T cells show 608 
reduced proliferation responses to MOG and effector cytokine production is not 609 
boosted in response to CD40 co-stimulation. This, together with the additional 610 
finding that exogenous IL-2 reversed the unresponsiveness of T cells to antigen 611 
stimulation shows that OM-MOG induces differential TCR signaling in MOG-specific T 612 
cells that results in selective functional anergy.  613 
 614 
CD3+ T cells infiltrate spinal cord leptomeninges and activate inflammatory 615 
macrophages in small lesions but do not induce clinical signs in OM-MOG-vaccinated 616 
mice 617 
To understand why the antigen-specific Th1 and Th17 cells that are primed in 618 
OM-MOG-vaccinated mice are not able to initiate EAE we next investigated whether 619 
T cells are able to infiltrate the parenchymal tissue of the spinal cord and trigger 620 
downstream effector mechanisms such as macrophage recruitment and activation. 621 
First we attempted to isolate mononuclear cells from the spinal cords of OM-MOG- 622 
and PBS-vaccinated EAE mice at the peak of disease in the PBS group (with clinical 623 
scores 3.5-4) and to measure the proportions of CD4+ T cells. In PBS-vaccinated mice 624 
CNS-infiltrating mononuclear cells were readily isolated and contained 625 
approximately 15% CD4+ T lymphocytes as measured by flow cytometry (data not 626 
shown). However, only very low numbers of CNS-infiltrating cells could be recovered 627 
from OM-MOG-vaccinated mice and flow cytometry analysis of these cells was not 628 
possible. 629 
We next investigated the tissue distribution of activated MOG-specific T cells 630 
and the extent of immune cell infiltration into the spinal cord during EAE in OM-631 
MOG-vaccinated mice by generating bone marrow chimeric mice. We reconstituted 632 
lethally-irradiated C57BL/6 wild-type mice with bone marrow cells isolated from 633 
double transgenic TgEGFP x 2D2 mice. Chimeric mice showing ≥70% reconstitution of 634 
blood leukocytes by GFP+ cells, as measured by flow cytometry, were vaccinated and 635 
immunized for MOG-EAE. Immunohistochemical analysis of gut, lung and spinal cord 636 
taken at the peak of EAE in the PBS-treated group using anti-GFP antibodies showed 637 
bone marrow-derived cells distributed in the lamina propria and submucosa of the 638 
gut, Peyer’s patches of the ileum, lung tissue and large confluent lesions in the white 639 
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matter of the spinal cord (Supplementary Fig. 4). Immunostaining of serial sections 640 
with anti-CD3 antibody did not reveal any T cells in gut or lung but showed 641 
numerous T cells distributed throughout the spinal cord lesions (Fig. 6a). OM-MOG-642 
vaccinated mice showed a similar distribution as controls of GFP-immunoreactive 643 
cells in the gut and lung and no CD3+ T cells were detected in these tissues. In the 644 
spinal cord, consistent with the histopathological analysis (Fig. 1d), the numbers of 645 
recruited GFP-immunoreactive (Supplementary Fig. 4) and CD3-immunoreactive cells 646 
(Fig. 6a) were markedly reduced compared to EAE controls. Both CD3+ T cells and 647 
GFP-immunoreactive immune cell infiltrates were restricted to the leptomeninges or 648 
occasional small compact lesions in the white matter (Fig. 6a). Interestingly, these 649 
lesions were detected in mice that displayed no clinical signs on any day of follow-650 
up.  651 
To address whether the reduced antigen-specific T cell proliferation 652 
measured in secondary lymphoid organs of OM-MOG-vaccinated mice following 653 
MOG immunization, and in 2D2 T cells co-cultured with OM-MOG DC, might be 654 
responsible for reduced immune cell infiltration of the spinal cord in OM-MOG-655 
vaccinated mice during EAE we performed double immunofluorescence staining 656 
using antibodies to CD3 and Ki67, a marker of cell proliferation. In PBS-treated mice, 657 
a small proportion of CD3+ T cells distributed throughout the tissue lesions and 658 
leptomeninges showed Ki67-immunoreactivity (Fig. 6b), indicating that proliferation 659 
of T cells occurs in white matter lesions during EAE. This is consistent with the 660 
findings of Wekerle and colleagues that T cells enter the brain in the "migratory" 661 
phenotype, encounter their specific antigen at APC in meninges and perivascular 662 
spaces, proliferate and acquire the ability to pass the astrocytic glia limitans and 663 
invade the CNS parenchyma (Lodygin, Odoardi, Schlager, Korner, Kitz, Nosov, van 664 
den Brandt, Reichardt, Haberl, and Flugel, 2013), (Mues, Bartholomaus, Thestrup, 665 
Griesbeck, Wekerle, Kawakami, and Krishnamoorthy, 2013). In OM-MOG-treated 666 
mice, similarly small proportions of CD3+ T cells showed Ki67-immunoreactivity (Fig. 667 
6b) although, as mentioned above, the overall numbers of T cells were markedly 668 
reduced compared to EAE controls, and were differentially distributed, being 669 
detected only in leptomeninges (Fig. 6a). No double-labeled CD3+Ki67+ cells were 670 
detected in the parenchymal lesions in OM-MOG-vaccinated mice.  671 
We further investigated whether T cells in OM-MOG-vaccinated mice can 672 
trigger downstream effector mechanisms such as macrophage recruitment and 673 
activation in the spinal cord, by analyzing the accumulation of p22phox, which is an 674 
essential subunit of NADPH oxidases, and iNOS, in sections from mice that had been 675 
vaccinated with OM-MOG or PBS, as shown in Fig. 1d. In the active MOG-EAE model 676 
used in this study, tissue injury is associated with massive infiltration of the tissue by 677 
CD3+ T cells and the presence of numerous macrophage-like cells showing p22phox 678 
and iNOS expression (Schuh, Wimmer, Hametner, Haider, Van Dam, Liblau, Smith, 679 
Probert, Binder, Bauer, Bradl, Mahad, and Lassmann, 2014). Here, PBS-vaccinated 680 
mice showed typical spinal cord lesions of MOG-EAE, with numerous CD3+ T cells and 681 
p22phox- and iNOS-immunoreactive macrophage-like cells (Fig. 6b, first and second 682 
columns). Surprisingly, OM-MOG-vaccinated mice also showed sparse infiltration of 683 
the spinal cord by CD3+ T cells and p22phox- and iNOS-immunoreactive macrophage-684 
like cells which were much fewer in number and, as mentioned above, limited to 685 
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leptomeninges or to exceptional compact white matter lesions (Fig. 6b, third and 686 
fourth columns).  687 
 688 
Overall, these data show that antigen-specific CD3+ T cells traffic to the spinal cord in 689 
OM-MOG-vaccinated mice during the development of EAE, and locally activate 690 
macrophage-like cells to produce reactive oxygen and nitrogen species, although 691 
numbers are greatly reduced and mainly restricted to leptomeninges compared to 692 
the large confluent white matter infiltrates typical of EAE in PBS-treated control 693 
mice.  694 
  695 
696 
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Discussion 697 
 698 
In this study we describe a method for targeting myelin peptide antigens to APC and 699 
inducing robust peptide-specific T cell tolerance in mice, protecting them against the 700 
development of EAE when administered as i.d. injection in prophylactic (vaccination) 701 
or therapeutic protocols and in the presence of strong immune stimulants such as 702 
PTx and agonistic anti-CD40 antibody. EAE-inducing myelin peptide epitopes were 703 
synthesized with a (Lys-Gly)5 linker and chemically conjugated to the polysaccharide 704 
mannan, a ligand for the MR, in its oxidized or reduced form. Specifically, we 705 
conjugated mannan to H-2b binding (MOG35-55) and H-2
s binding (PLP139-151) myelin 706 
peptides and show that they protect mice against the induction of EAE in two 707 
different models, a chronic form induced in C57BL/6J (H-2b) mice by immunization 708 
with MOG/CFA/PTx and a relapse-remitting form induced in SJL/J  (H-2s) mice by 709 
immunization with PLP/CFA, respectively. Tolerance in both models was peptide 710 
specific and, as further studied in the MOG-EAE model, was associated with reduced 711 
antigen-specific T cell proliferation but not changes in differentiation of IFN-γ-712 
producing Th1, IL-17-producing Th17 cells or regulatory T cells. However, we 713 
identified resistance in antigen-specific Th1 and Th17 towards CD40-mediated co-714 
stimulatory signals from APC. This dissociation between proliferation and cytokine 715 
production in T cell responses indicates that the presentation of OM-MOG by APC 716 
results in differential signaling through the TCR on MOG-specific T cells compared to 717 
presentation of MOG, and that this results in partial T cell anergy. Indeed, CD3+ T 718 
cells and activated macrophages accumulated in the leptomeninges of the spinal 719 
cord in OM-MOG-vaccinated mice after immunization with MOG, suggesting that 720 
MOG-specific T cells recognize target tissue and initiate inflammation. However, 721 
markedly reduced numbers of T cells infiltrated the CNS parenchyma to form 722 
inflammatory lesions compared to PBS-vaccinated EAE controls, and mice that 723 
developed lesions did not necessarily develop clinical signs of EAE. Overall, our 724 
results suggest that OM-MOG induces the expansion of Th1 and Th17 T cells that 725 
show impaired proliferation responses to antigen and APC-induced co-stimulatory 726 
signals that are required for licensing them to become fully pathogenic T cells.  727 
 728 
Peripheral tolerance can be induced by via several mechanisms including T cell 729 
deletion or anergy, the induction of regulatory T cells and immune deviation (Tisch, 730 
2010). To gain insight into the mechanism of OM-MOG-induced tolerance we 731 
monitored T cell responses to MOG stimulation in vivo in conjugate-vaccinated mice 732 
and in vitro using DC-T cell co-cultures. We found no evidence for deletion of 733 
antigen-specific T cells in the periphery of OM-MOG-vaccinated mice, as judging 734 
from the normal differentiation of IFN-γ- and IL-17-producing CD4+ T cells and FoxP3+ 735 
regulatory T cells isolated from secondary lymphoid organs following immunization 736 
of mice with MOG. This was supported by data from DC-T cells cultures showing that 737 
OM-MOG DC and MOG DC stimulated equal production of IFN-γ and IL-17 by CD4+ 738 
2D2 T cells, and that OM-MOG DC did not induce increased cell surface expression of 739 
the apoptosis marker annexin V compared to MOG, OM or PBS DC. Furthermore, we 740 
found no evidence for immune deviation in antigen-specific T helper cell populations 741 
and no alteration in regulatory T cell populations. We did, however, detect reduced 742 
antigen-specific T cell proliferation measured both in secondary lymphoid organs of 743 
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OM-MOG-vaccinated mice following MOG immunization, and in 2D2 T cells co-744 
cultured with OM-MOG DC, as well as failure of OM-MOG DC-delivered co-745 
stimulatory signals to up-regulate T cell cytokine production. The uncoupling of 746 
cytokine production from proliferation in T cells in the presence of competent APC 747 
has been described previously in response to APL (Evavold et al., 1991) and during 748 
oral tolerance (Whitacre, Gienapp, Orosz, and Bitar, 1991), (Chen, Inobe, Kuchroo, 749 
Baron, Janeway, Jr., and Weiner, 1996), (Karpus, Kennedy, Smith, and Miller, 1996) 750 
and is thought to involve the differential activation of TCR signaling pathways (Sloan-751 
Lancaster and Allen, 1996). Although the signaling pathways that underlie 752 
differential TCR-mediated effects remain to be fully elucidated, our findings add that 753 
effector T cell cytokine production, in the absence of adequate proliferative 754 
response, is not sufficient for the induction of EAE.  755 
 756 
The mechanism by which mannan-conjugated myelin peptides reduce the 757 
encephalitogenic function of effector T cells therefore appears to be different from 758 
those previously described for immune tolerance induced by APC targeting which 759 
include association with CD5 expression (Hawiger et al., 2004), reduction of IL-17 cell 760 
and increase of regulatory T cell differentiation (Stern et al., 2010) and immune 761 
deviation towards an immunoregulatory profile (Apostolopoulos et al., 2000), 762 
(Apostolopoulos et al., 1995). It most closely resembles tolerance induced by 763 
mannosylated antigens, as previously described Nagelkerken and his group. Like 764 
mannan-MOG, mannosylated PLP139-151 protected SJL mice against the development 765 
of PLP-EAE through an active mechanism, because it inhibited disease when 766 
administered after EAE induction by active immunization with PLP or adoptive 767 
transfer of PLP139-151-reactive T cell blasts (Luca et al., 2005), (Kel et al., 2007). Also 768 
lymph node cells isolated from mice that had been immunized with mannosylated 769 
PLP139-151 showed equal cytokine and chemokine production but reduced 770 
proliferation responses compared to cells primed with non-mannosylated PLP139-151 771 
(Kel et al., 2008). This defect was associated with poor Th1 effector functions as 772 
shown by reduced IgG2a antibody levels, reduced DTH responses and EAE symptoms 773 
(Luca et al., 2005), (Kel et al., 2007). However, unlike tolerance induced by OM-MOG, 774 
which was resistant to PTx, that induced by mannosylated peptides was abrogated 775 
by PTx administration (Kel et al., 2008). PTx is widely used to increase antigen-776 
specific T cell responses and disease susceptibility in EAE models through multiple 777 
effects including prevention of antigen-induced peripheral T cell anergy (Kamradt, 778 
Soloway, Perkins, and Gefter, 1991), induction of IL-17 production (Hofstetter, Grau, 779 
Buttmann, Forsthuber, Gaupp, Toyka, and Gold, 2007) and reduction of regulatory T 780 
cells (Chen, Winkler-Pickett, Carbonetti, Ortaldo, Oppenheim, and Howard, 2006). It 781 
is possible therefore, that mannosylated and mannan-conjugated peptides induce T 782 
cell tolerance through a similar mechanism and that differences in sensitivity of the 783 
two approaches to immune adjuvants reflect differences in the strength of tolerance 784 
induced.  785 
 786 
The MR is expressed by most tissue macrophages, other cell types including hepatic 787 
and lymphatic endothelia, a subpopulation of DC in lymphoid organs that drain the 788 
periphery and in brain meningeal macrophages and perivascular microglia in the 789 
mouse (McKenzie, Taylor, Stillion, Lucas, Harris, Gordon, and Martinez-Pomares, 790 
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2007), (Linehan et al., 1999) as well as additional skin and gut DC in humans 791 
(Engering, Geijtenbeek, van Vliet, Wijers, van, Demaurex, Lanzavecchia, Fransen, 792 
Figdor, Piguet, and van, 2002). It provides an efficient internalization system for the 793 
recognition, transport and clearance of host-derived glycoproteins and microbe-794 
derived ligands (Taylor, Martinez-Pomares, Stacey, Lin, Brown, and Gordon, 2005). 795 
Previous studies showed that engagement of the MR by mannosylated 796 
lipoarabinomannans, mannan or an anti-MR antibody inhibited LPS-induced IL-12 797 
production by human DC (Nigou, Zelle-Rieser, Gilleron, Thurnher, and Puzo, 2001) 798 
and Toll-like receptor-dependent IL-12 production in mouse macrophage cells 799 
(Pathak, Basu, Bhattacharyya, Pathak, Kundu, and Basu, 2005). Also some, not all, 800 
natural MR ligands activated an anti-inflammatory program in human monocyte-801 
derived DC, which included inhibition of IL-12 production and potential to polarize 802 
Th1 effector cells (Chieppa, Bianchi, Doni, Del, Sironi, Laskarin, Monti, Piemonti, 803 
Biondi, Mantovani, Introna, and Allavena, 2003). These latter studies show that 804 
appropriate engagement of the MR on DC can elicit immunosuppressive effects. To 805 
investigate the cellular basis of MOG-specific T cell tolerance in OM-MOG-vaccinated 806 
mice, we used DC cultures derived from mouse bone marrow and unexpectedly 807 
found that OM-MOG-loaded DC displayed phenotypic and functional characteristics 808 
of immune-promoting mature DC. First, DC loaded with OM-MOG or MOG efficiently 809 
presented antigen to 2D2 MOG-specific T cells and equally induced the 810 
differentiation of IFNγ-producing and IL-17-producing T cells. Second, both OM and 811 
OM-MOG increased the surface expression of CD40, CD80 and CD86 in DC to levels 812 
at least as high as LPS-treated DC, showing that mannan induces the phenotypic 813 
maturation of bone marrow-derived DC, a property consistent with its functional 814 
characteristics as a PAMP, and in agreement with our previous results on the effects 815 
of OM-MUC1 in bone marrow-derived DC as well as in vivo splenic and lymph node 816 
DC (Sheng et al., 2006). Third, OM-MOG DC showed CD40-inducible production of 817 
the Th1 and Th17 polarizing cytokines, IL-12 and IL-23 respectively, properties that 818 
are essential for the immune-promoting functions of mature DC (Caux, Massacrier, 819 
Vanbervliet, Dubois, Van, Durand, and Banchereau, 1994), (Cella, Scheidegger, 820 
Palmer-Lehmann, Lane, Lanzavecchia, and Alber, 1996), (Koch, Stanzl, Jennewein, 821 
Janke, Heufler, Kampgen, Romani, and Schuler, 1996), (Iezzi et al., 2009). These 822 
results first of all suggest that T cell tolerance induced by the administration of OM-823 
MOG in mice is not due to an intrinsic defect in APC function. Our finding that OM-824 
MOG induces T cell tolerance, and that in vitro grown OM-MOG-loaded DC are 825 
sufficient to transfer tolerance into mice with ongoing EAE therefore appears 826 
paradoxical. A number of previous studies have already challenged the concept that 827 
only immature and semi-mature DC mediate T cell tolerance by showing that 828 
phenotypically mature DC can also induce tolerance (Albert et al., 2001), (Menges, 829 
Rossner, Voigtlander, Schindler, Kukutsch, Bogdan, Erb, Schuler, and Lutz, 2002), 830 
(Fujii et al., 2004), (Sporri et al., 2005). In some of these studies (Albert et al., 2001), 831 
(Fujii et al., 2004), but not all (Menges et al., 2002), stimulation of CD40 changed the 832 
outcome of tolerance to immunity. Since various cell types express the MR in mice it 833 
is possible that tolerance induced by OM-MOG is mediated by APC other than DC, 834 
for example by meningeal macrophages or perivascular microglia (Linehan et al., 835 
1999) which are known to have APC properties (Greter, Heppner, Lemos, Odermatt, 836 
Goebels, Laufer, Noelle, and Becher, 2005). Nevertheless, when we administered 837 
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FGK45 in vivo it did not change the outcome of protection against EAE in OM-MOG-838 
vaccinated mice while, as expected, it exacerbated disease in PBS-vaccinated mice. 839 
Taken together, our findings show that mannan-peptide-targeted APC do not show 840 
overt functional defects; on the contrary they show characteristics of mature 841 
immunogenic APC; and suggest they play a nonautonomous role in mediating the 842 
tolerogenic effects of OM-MOG to T cells.    843 
 844 
Lymphocytes derived from OM-MOG-tolerized mice and MOG-specific T cells 845 
exposed to OM-MOG DC exhibited a selective defect in proliferation, but not 846 
cytokine responses to antigen stimulation and this unresponsiveness was overcome 847 
by exogenous IL-2. Clonal T cell anergy, characterized by reduction of antigen-848 
specific proliferation responses but not necessarily changes in cytokine production, 849 
has been described as a mechanism of T cell tolerance induced by oral 850 
administration of MBP (Whitacre et al., 1991), (Chen et al., 1996) and PLP139-151 851 
(Karpus et al., 1996), by myelin peptide-coupled splenocytes (Vandenbark, Celnik, 852 
Vainiene, Miller, and Offner, 1995) and by prostaglandin 2 (Mannie, Prevost, and 853 
Marinakis, 1995). In oral tolerance, low doses of antigen generate regulatory T cells 854 
whereas high doses induce T cell anergy or deletion. Our data suggest that OM-MOG 855 
administration in mice results in strong stimulation of self-reactive T cells by APC, 856 
through combined MOG-TCR-specific and MR-induced innate immune signals, that 857 
results in partial T cell anergy. This would be in line with our previous findings, where 858 
OM-MUC1 greatly enhanced T cell responses to MUC1 but, in that case, promoted 859 
anti-tumor immunity (Apostolopoulos et al., 1995). Our finding that T cell tolerance 860 
in OM-MOG vaccinated EAE mice and OM-MOG DC-T cell cultures was not altered by 861 
CD40 co-stimulation is a strong indication of clonal T cell anergy because mice that 862 
are deficient in CD40 do not develop pathogenic Th17 T cells and are completely 863 
resistant to EAE (Becher et al., 2001), (Iezzi et al., 2009). It is established that de novo 864 
processing and presentation of CNS antigens in the context of MHC class II is 865 
absolutely required for the development of EAE (Tompkins et al., 2002), (Becher, 866 
Durell, and Noelle, 2003), (Kawakami, Lassmann, Li, Odoardi, Ritter, Ziemssen, 867 
Klinkert, Ellwart, Bradl, Krivacic, Lassmann, Ransohoff, Volk, Wekerle, Linington, and 868 
Flugel, 2004) probably by APC associated with the meninges and CNS vasculature 869 
(Greter et al., 2005). Previous studies showed that mannosylated PLP could 870 
ameliorate EAE when administered after the induction of EAE by adoptive transfer of 871 
activated myelin-reactive T cells (Kel et al., 2007), showing that tolerance is actively 872 
induced in already activated T cells, possibly preventing their reactivation in the 873 
periphery or CNS. Similarly in this study administration of OM-MOG, either as i.d. 874 
injection or transferred with DC, actively induced tolerance in resting or already 875 
activated T cells, thereby reducing their proliferation and encephalitogenic potential 876 
and protecting mice against EAE. In line with the hypothesis that OM-MOG acts by 877 
reducing the capacity of MOG-specific T cells to be restimulated by endogenous 878 
antigen in the target tissue, is the finding that CD3+ T cells accumulated in the 879 
leptomeninges and vasculature of the spinal cord and showed markedly reduced 880 
infiltration of the parenchyma after the induction of active EAE. Alternatively, it is 881 
possible that OM-MOG exerts a decoy effect, diverting the migration of MOG-882 
specific T cells away from targets in the CNS to the site of injection in the skin, and 883 
further in vivo experiments will be needed to investigate this possibility. 884 
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 885 
Overall, mannan-conjugated peptides administered as prophylactic vaccines or 886 
therapeutically induce potent and reproducible peptide-specific protection of mice 887 
from the clinical signs of EAE with all protocols tested even in the presence of strong 888 
APC maturation stimuli. The protective effect of mannan-conjugated peptides is 889 
especially important in a setting where EAE is induced in the presence of adjuvants, 890 
like PTx and CD40, that have the ultimate role of breaking tolerance indicating that it 891 
might be a powerful strategy to silence autoimmunity in a human setting where 892 
immune challenge by microbial antigens is thought to play a key role in the 893 
breakdown of immune tolerance to self-antigens. Further studies are needed to 894 
characterize the mechanism of anergy triggered by TCR stimulation by mannan-895 
peptide conjugates, especially since they constitute interesting targets of clinical 896 
application for therapeutic intervention in MS. Treatment with mannan-conjugated 897 
autoantigens could differ from current therapeutic regimens that are 898 
immunosuppressive and could be a step towards the design of personalized 899 
therapies for the different immunodominant peptide epitopes found in autoantigen 900 
specific immune reactions in MS and relevant demyelinating disorders.   901 
902 
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Figure legends  928 
FIGURE 1. Administration of OM-MOG or RM-MOG in prophylactic (vaccination) or 929 
therapeutic protocols attenuates the development of MOG-induced EAE in C57BL/6 930 
mice. (a) Mean clinical scores of MOG-EAE in groups of mice that were vaccinated i.d. 931 
with dilute soluble OM-MOG, RM-MOG, OM, RM or PBS at indicated time points 932 
(arrows) prior to the induction of EAE by immunization with MOG/CFA/PTx (n = 6 for 933 
each group). (b) Mean clinical scores of MOG-EAE in groups of mice that received i.d. 934 
administration of dilute soluble peptides on day 0 and 7 relative to immunization for 935 
EAE induction (n=5 for each group). (c) Mean clinical scores of MOG-EAE in groups of 936 
mice injected i.d. with dilute soluble peptides at indicated time points after 937 
immunization for EAE induction (n = 5 for each group). The results shown are from one 938 
representative of two (a, c) or three (b) independent experiments. (d, e) Vaccination 939 
with OM-MOG protects C57BL/6 mice from spinal cord inflammation and demyelination 940 
during MOG-EAE. (d) Inflammatory cell infiltration was visualized by H&E (left column) 941 
and demyelination by Luxol fast blue (right column) staining of spinal cord sections 942 
taken from representative mice in the different vaccination groups on day 24 943 
following immunization for the induction of MOG-EAE. Representative sections from 944 
1 of 5 animals per group are shown. (e) Quantification of spinal cord inflammation 945 
(black bars) and demyelination (grey bars) as well as brain demyelination (white bars) in 946 
all experimental groups. Representative data from 5 animals per group are shown. 947 
Statistical significance after pair-wise comparisons of each experimental group with the 948 
non-vaccinated control (PBS) group is shown (*, p<0.05). Triangles (a) indicate time 949 
points where pairwise comparison between OM-MOG and RM-MOG groups also show 950 
significant differences. 951 
 952 
FIGURE 2. Protection of mice against EAE by mannan-peptides is peptide-specific. (a) 953 
Vaccination of SJL/J mice with OM-PLP139-151, but not OM-MBP83-99, attenuated the 954 
development of PLP-EAE. Mean clinical scores of PLP-EAE in groups of mice that were 955 
vaccinated with OM- PLP139-151, OM- MBP83-99 or PBS on the days indicated (arrows) 956 
prior to immunization for the induction of PLP-EAE (n = 5 for all groups). (b) Vaccination 957 
of C57BL/6 mice with OM-MOG35-55, but not OM-PLP178-191, attenuated the 958 
development of MOG-EAE. Mean clinical scores of MOG-EAE in groups of mice that 959 
were vaccinated with OM-MOG35-55, OM-, PLP178-191 or PBS on the days indicated 960 
(arrows) prior to the induction of PLP-EAE by immunization with PLP/CFA (n = 5 for all 961 
groups). Data are from one representative of two independent experiments. Statistical 962 
significance after pair-wise comparisons of each experimental group with the non-963 
vaccinated control (PBS) group is shown (*, p<0.05). 964 
 965 
FIGURE 3. Antigen-specific responses of T cells exposed to OM-MOG show reduced 966 
proliferation but normal expansion of Th1, Th17 and regulatory T cell populations. 967 
(a) Proliferation of splenocytes isolated from vaccinated mice 25 days post-968 
immunization for MOG-EAE. Splenocytes were stimulated ex vivo with MOG (mice 969 
vaccinated with PBS n = 4; OM-MOG n = 6; RM-MOG n = 6; OM n = 5; RM n = 4). (b) 970 
Proliferation of CFSE-labelled MOG-specific 2D2 CD45.1+ cells in vivo after i.v. transfer 971 
into recipient CD45.2+ mice that had received a complete vaccination protocol with 972 
mannan-conjugated peptides, on day 2 after MOG-EAE induction. DLN were isolated 973 
from mice 7 days after immunization with MOG/CFA/PTx, and on the CD45.1+ gate the 974 
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percentages of proliferating cells (showing low and intermediate levels of CFSE staining) 975 
were measured (mice vaccinated with MOG n = 5; OM-MOG n=5; OM n=5; PBS n=5). 976 
Right panels show representative histogram plots showing CFSE dilution in MOG-977 
specific 2D2 CD45.1+ cells in DLN isolated from OM- and OM-MOG-vaccinated mice. (c-978 
d) Antigen priming of Th1 and Th17 T cells is normal in mice vaccinated with OM-MOG. 979 
Mice were vaccinated with OM, OM-MOG, MOG or a mix of unconjugated OM and 980 
MOG and immunized for the induction of MOG-EAE. (c) The production of IFN-γ and IL-981 
17 by CD4+ T cells from DLN isolated 7 days after MOG immunization was measured by 982 
intracellular cytokine staining (n=5 for the MOG and OM-MOG groups and n=4 for the 983 
OM and OM/MOG groups). (d) The production of IL-17 by CD4+ T cells from DLN (left 984 
panel) and spleen (right panel) isolated on days 10 (pre-onset) and 15 (peak) of EAE was 985 
also measured by intracellular cytokine staining (n = 5 for all groups). (e) The 986 
production of IL-10 by CD4+ T cells from DLN isolated on day 13 of EAE was also 987 
measured by intracellular cytokine staining (n = 4 for all groups). (f) Proportions of 988 
CD4+FoxP3+ cells in DLN cells from vaccinated mice 7 days post-immunization for MOG-989 
EAE, and stained for surface CD4 and intracellular FoxP3 (n=5 mice in each group). Right 990 
panel, representative dot plots are shown from each experimental group. Data are 991 
from one (e) or one representative of two independent experiments. Statistical 992 
significance after pair-wise comparisons (using Student’s t test) of each experimental 993 
group with the non-vaccinated control (PBS) group is shown. 994 
 995 
FIGURE 4. OM-MOG-loaded DC up-regulate cell surface maturation markers, Th1 and 996 
Th17 polarising cytokines and down-regulate PD-L1 and are sufficient to transfer 997 
tolerance into EAE mice. (a) Flow cytometry of DC loaded with PBS or peptide 998 
conjugates or incubated with LPS (1 μg /ml), showing frequency of CD11c+ cells 999 
expressing DC surface maturation markers. (b) Enzyme-linked immunosorbant assay of 1000 
cytokines in culture supernatants of DC loaded with OM-MOG or MOG in the absence 1001 
or presence of FGK 45 agonistic anti-CD40 antibody (10 μg/ml) for 72 hr. (c) Flow 1002 
cytometry of DC loaded with PBS or peptide conjugates showing frequency of CD11c+ 1003 
cells expressing PD-L1 surface marker. (d) Mean clinical scores of mice that were 1004 
immunized for the induction of MOG-EAE and 8 days later received i.v. transfer of bone 1005 
marrow-derived DC loaded ex vivo with OM-MOG (n=9), unconjugated MOG (n = 8), 1006 
OM (n = 7) or PBS (n = 8) at the indicated time point (arrow). Data are from two (b, d) 1007 
or three (a) independent experiments. Statistical significance after pair-wise 1008 
comparisons between groups or (d) or each experimental group with the non-1009 
vaccinated control (PBS) group (*, p<0.05) is shown. 1010 
 1011 
FIGURE 5. OM-MOG DC induce normal maturation of MOG-specific Th1 and Th17 1012 
responses but reduced T cell proliferation and CD40 costimulation responses. (a, b) 1013 
Antigen presentation assays between MOG DC and OM-MOG DC and 2D2 MOG-1014 
specific lymphocytes at a 1:5 DC:T cell ratio in the absence or presence of FGK45 1015 
agonistic anti-CD40 antibody (10 μg/ml) for 72 hr. (a) Proliferation of 2D2 lymphocytes 1016 
by peptide-loaded DC as measured by [3H] thymidine incorporation. (b) Production of 1017 
IFN-γ and IL-17 by CD4+ 2D2 T cells in response to peptide-loaded DC as measured by 1018 
intracellular cytokine staining. (c) Annexin V+ surface expression by CD4+ 2D2 MOG-1019 
specific T cells stimulated by OM-MOG, MOG, OM and PBS DC. Annexin V translocation 1020 
was measured at day 7 of culture. Statistical significance after pair-wise comparisons 1021 
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(using Student’s t test) between 2D2 cells stimulated with PBS DC versus Ag DC is 1022 
shown. (d) Mean clinical scores of MOG-EAE in groups of mice that were vaccinated i.d. 1023 
with dilute soluble OM-MOG or PBS and were further left untreated or treated by 1024 
twice weekly i.p. injections of FGK45 agonistic anti-CD40 antibody (90 1025 
μg/mouse/injection) from day 2 post-immunization (n = 8 for the OM-MOG and OM-1026 
MOG + aCD40 groups; n = 4 for the PBS and the PBS + aCD40 groups). (e) Proliferation 1027 
of 2D2 lymphocytes by peptide-loaded as measured by [3H] thymidine incorporation in 1028 
the absence or presence of recombinant IL-2 (10 ng/ml). Representative results from 1029 
one of two independent experiments are shown. Statistical significance after pair-wise 1030 
comparisons between cells or mice treated in the absence or presence of agonistic anti-1031 
CD40 antibody (a-d) (*, p<0.05) or IL-2 (e) is shown. 1032 
 1033 
 1034 
FIGURE 6. CD3+ T cell and immune cell infiltration of the spinal cord in OM-MOG-1035 
vaccinated mice is sparce and limited to leptomeninges or exceptional compact 1036 
white matter lesions. (a) Double immunofluorescence staining with anti-CD3 and anti-1037 
Ki67 antibodies identifies proliferating CD3+ T cells in spinal cord sections taken at the 1038 
peak of disease from chimeric C57BL/6 mice reconstituted with bone marrow from 1039 
TgEGFP mice, vaccinated with OM-MOG or OM control and immunized for MOG-EAE. 1040 
Numerous CD3-immunoreactive infiltrating cells are seen in the parenchyma of PBS-1041 
vaccinated mice, many of which also show Ki67-immunoreactivity (clinical score 3.5) 1042 
(upper panel, arrowheads). CD3-immunoreactive infiltrates are markedly reduced in 1043 
OM-MOG vaccinated mice (clinical score 0) where they are mainly restricted to 1044 
leptomeninges and the associated perivascular spaces (lower panel). (b) Oxidative burst 1045 
in infiltrating cells shown by immunostaining of sections from the same mice as in a) 1046 
with anti-p22phox (p22) and iNOS antibodies in areas of CD3+ T cell infiltration. 1047 
Representative results from 5 mice per group are shown. Scale bars 500 μM (a). 1048 
1049 
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